Citations

Clear

1707 citation(s) found for "He, Philip".

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.
Glucagon‐Like Peptide‐1 Receptor Agonism and Muscle Health: Vascular and Myocellular Effects on Glucose and Protein Metabolism
Atherton, Philip J. , Katsanos, Christos S. , Liu, Zhenqi

Mayo Clinic

Comprehensive Physiology | March 17, 2026 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/cph4.70126 | PMID 41839621 Get It

ABSTRACT Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1 RAs) improve glycaemia and reduce body weight, yet their organ‐level actions on skeletal muscle remain incompletely defined. Framing skeletal muscle as an integrated unit of vasculature and muscle cells, we synthesize evidence with emphasis on glucose and protein metabolism. GLP‐1 and GLP‐1 RAs recruit microvasculature in muscle, expanding capillary surface area and increasing delivery of insulin, glucose, and amino acids. Microvascular recruitment increases interstitial insulin availability and potentiates insulin‐stimulated glucose uptake and glycogen synthesis, whereas direct effects of GLP‐1 on muscle cells remain under investigation. For protein metabolism, microvascular recruitment can enhance muscle protein synthesis when plasma amino acid availability is elevated, whereas effects under basal (fasted) conditions remain unclear. Elucidating the uncertainty regarding GLP‐1 receptor localization in human muscle cells will clarify whether direct signaling occurs within muscle cells, thereby improving our understanding of the relative contribution of direct versus perfusion‐mediated actions of GLP‐1 RAs. Clinically, GLP‐1 RAs reduce lean body mass, likely reflecting energy‐deficit–mediated effects, but studies directly assessing muscle mass are still limited. Overall, current evidence indicates that GLP‐1 RAs exert beneficial effects on muscle vasculature and muscle glucose metabolism. However, their influence on muscle protein turnover remains unclear—primarily due to observed reductions in muscle mass—despite preclinical data suggesting potential favorable effects on muscle protein metabolism that remain to be confirmed in humans.
Postural Orthostatic Tachycardia Syndrome and Chronic Orthostatic Intolerance: Common, Challenging, and Manageable
Klaas, Kelsey , Fischer, Philip R.

Mayo Clinic

Pediatric Annals | March 5, 2026 | Volume: 55 | Issue: 3 | Pages: No page available

10.3928/19382359-20260112-02 | PMID 41784482 Get It

Positron Emission Tomography/Computed Tomography in Cardiac Implantable Electronic Device Infections: Insights From the Emerging Infections Network
McHugh, Jack , Cuervo, Guillermo, Abu-Zeinah, Khalid , Beekmann, Susan E. , Polgreen, Philip M. , Deshmukh, Abhishek J, Johnson, G B, Saleh, Omar M Abu, Baddour, L M, Baddour, Larry M. , Johnson, Geoffrey B. , Cuervo, Guillermo , Chesdachai, Supavit , McHugh, Jack , Cuervo, Guillermo , Abu-Zeinah, Khalid , Beekmann, Susan E , Polgreen, Philip M , Deshmukh, Abhishek J , Johnson, Geoffrey B , Abu Saleh, Omar , DeSimone, Daniel C , Baddour, Larry , Chesdachai, Supavit , Deshmukh, Abhishek , Saleh, Omar Abu , DeSimone, Daniel C.

Mayo Clinic

Open Forum Infectious Diseases | March 3, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/ofid/ofag109 | PMID 41852557 Get It

Abstract The practice patterns of fluorine 18–labeled fluorodeoxyglucose positron emission tomography/computed tomography ([18F] FDG PET/CT) use in cardiac implantable electronic device infection remain undefined. Among 258 Emerging Infections Network respondents, 69% reported never or rarely using [18F] FDG PET/CT. Limited access and insurance barriers were the most common obstacles.
Recommendations for the Deprescribing of Psychotropic Medications
Goldberg, Joseph F. , McIntyre, R. S., Freeman, Marlene P. , Mago, Rajnish, Citrome, Leslie, Rosenblat, Joshua D., Thase, Michael E., Tohen, Mauricio, Vieta, Eduard, Malhi, Gin S, Sajatovic, M., Shelton, Richard C. , Macaluso, Matthew , Berk, Michael, Perlis, Roy H., Ostacher, Michael J., Khan, Arifulla, Sanacora, Gerard , Kane, John M., D, Goodman, Nierenberg, Andrew A., Correll, Christoph U., Kupka, R. W., Kasper, Siegfried, Furukawa, Toshi A., Davis, Lori L., Aaronson, Scott T., Gitlin, Michael , Jha, Manish K., Cohen, Lawrence J. , Papakostas, George I. , Mitchell, Philip B., Gorwood, P., Gupta, Swapnil , Frye, Mark A., Young, A. H., Zohar, Joseph, Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H. , Shelton, Richard C. , Young, Allan H. , Ostacher, Michael J. , Jha, Manish K. , Young, Allan H , Jha, Manish K , Ostacher, Michael J , McIntyre, Roger S. , Swartz, Holly A. , Citrome, Leslie , Rosenblat, Joshua D. , Thase, Michael E. , Tohen, Mauricio , Vieta, Eduard , Malhi, Gin S. , Sajatovic, Martha, Berk, Michael , Perlis, Roy H , Iosifescu, Dan Vlad , Rubio, Jose M , Kane, John M. , Nierenberg, Andrew A. , Correll, Christoph Ulrich , Kupka, Ralph , Kasper, Siegfried , Furukawa, Toshi A , Aaronson, Scott T. , Mitchell, Philip B , Gorwood, Philip , Frye, Mark A. , Zohar, Joseph , Zarate, Carlos A.

Mayo Clinic

JAMA Network Open | February 25, 2026 | Volume: 9 | Issue: 2 | Pages: e260043

10.1001/jamanetworkopen.2026.0043 | PMID 41739481 Get It

Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing. Objective To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing. Findings Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.
Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition
Cogswell, Petrice M, Therneau, Terry M, Hu, Mingzhao, Griswold, Michael E, Wiste, Heather J. , Machulda, Mary M., Braunstein, Joel B. , West, Tim, Verghese, Philip B. , Graff-Radford, Jonathan, Algeciras-Schimnich, Alicia, Lowe, Val J, Schwarz, Christopher G, Senjem, Matthew L, Gunter, Jeffrey L. , Knopman, David S, Vemuri, Prashanthi, Petersen, Ronald C, Jr, Clifford R Jack, Cogswell, Petrice M. , Cogswell, Petrice M , Lundt, Emily S. , Graff-Radford, Jonathan , Algeciras-Schimnich, Alicia , Schwarz, Christopher G , Knopman, David S. , Vemuri, Prashanthi , Jack, Clifford R , Lundt, Emily S , Therneau, Terry M. , Hu, Mingzhao, Griswold, Michael , Machulda, Mary M. , Stricker, Nikki H. , West, Tim , Graff‐Radford, Jonathan , Algeciras‐Schimnich, Alicia , Lowe, Val J. , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S. , Vemuri, Prashanthi , Petersen, Ronald C. , Jack, Clifford R.

Mayo Clinic

Brain | February 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag075 | PMID 41738322 Get It

Abstract Associations of Alzheimer’s disease biomarker progression with cognitive decline are important to inform patient prognosis. Of particular interest is how newly available plasma biomarkers evolve relative to cognitive decline. The goals of this work are to measure how much earlier versus later an individual’s progression on plasma and PET Alzheimer’s disease biomarkers is associated with earlier versus later cognitive progression and to estimate the average timeline of progression of these processes in the population. In this cohort study of 2369 Mayo Clinic Study of Aging (MCSA) and 1591 Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants, we fit non-linear mixed-effects models to estimate how much earlier versus later each individual progresses on plasma phosphorylated tau (p-tau)217, amyloid PET, tau PET and auditory verbal learning test (AVLT) sum of trials relative to the population mean (individual adjustment), the associations of these individual adjustments among biomarker pairs and how covariates affect the timing of biomarker progression. The association of individual adjustments implies mechanistic associations and the amount of variability in cognitive decline accounted for by each biomarker. By applying cut-off points, we also estimated the relative timing that these biomarkers become abnormal in the population. Associations of individual adjustments were moderate between all biomarkers and AVLT (R = 0.38–0.47) in the MCSA and stronger (R = 0.74–0.81) in ADNI; plasma p-tau217 accounted for 16% of the variability in timing of AVLT decline in the MCSA and 64% in ADNI. APOE ɛ4 carriership was associated with earlier biomarker progression. AVLT became abnormal after the biomarkers up to age 90, after which AVLT was estimated to become abnormal prior to tau biomarkers. The association of the timing of plasma and PET Alzheimer’s disease biomarker progression with cognitive decline was modest in the MCSA population-based sample and stronger in the Alzheimer’s disease-enriched ADNI cohort. The timing of plasma p-tau217 progression explained a similar degree of variability in AVLT progression as amyloid PET, supporting its utility as a marker of disease progression. The estimated temporal ordering of biomarkers and cognitive abnormality was as anticipated (amyloid, tau, cognition) up to the age of 90, beyond which AVLT was estimated to become abnormal prior to tau biomarkers, likely related to the effects of non-Alzheimer’s disease co-pathologies.
Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia
Paolillo, Emily W., Wise, Amy, Kaye, Jeffrey A., Beattie, Zachary , Dhanam, Sreya, Casaletto, Kaitlin B. , Saloner, Rowan, Mendez, Mario F., Vandevrede, Lawren, Ljubenkov, Peter A. , Seeley, William W., Gorno-Tempini, Maria Luisa, Miller, Bruce L., Heuer, Hilary W. , Forsberg, Leah K., Kornak, John , Boeve, Bradley F., Boxer, Adam L., Rosen, Howard J., Walsh, Christine M., Staffaroni, Adam M., Abdullah, Muhammad, Apostolova, Liana , Ece, Bayram, Botha, Hugo, Brushaber, Danielle , Clark, David, Considine, Ciaran , Darby, R. Ryan , Day, Gregory S., Dickerson, Bradford, Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily , Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana M., Galasko, Douglas R., Gavrilova, Ralitza, Gendron, Tania, Geschwind, Daniel, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Grossman, Murray, Hales, Chadwick M., Hall, Matthew, Honig, Lawrence S., Hsiung, Ging-Yuek (Robin), Huang, Eric S., Huey, Edward D, Irwin, David, Johnson, Noah, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler, Kwan, Justin Y., Lago, Argentina Lario , Lapid, Maria, Lavigne, Shannon B., Lee, Suzee, Litvan, Irene, Lucente, Diane , Mackenzie, Ian R., Masdeu, Joseph C. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pascual, Belen, Paulson, Henry, Petrucelli, Leonard, Pressman, Peter, Rademakers, Rosa, Ramanan, Vijay, Ramos, Eliana Marisa , Rankin, Katherine P., Rao, Meghana, Rascovsky, Katya, Rhoads, Kristoffer , Ritter, Aaron, Rogalski, Emily, Rojas, Julio C., Savica, Rodolfo, Snyder, Allison, Sullivan, Anna Campbell, Syrjanen, Jeremy, Tartaglia, M. Carmela, Taylor, Jack, Weintraub, Sandra, Wint, Dylan , Wong, Bonnie, Yokoyama, Jennifer, Mendez, Mario F. , VandeVrede, Lawren , Paolillo, Emily W. , Wise, Amy B. , Saloner, Rowan , Forsberg, Leah Kathleen, VandeVrede, Lawren , Mendez, Mario , Paolillo, Emily W , Kaye, Jeffrey , Au-Yeung, Wan-Tai Michael , Dhanam, Sreya , Seeley, William W. , Gorno‐Tempini, Maria Luisa , Forsberg, Leah K. , Kremers, Walter K. , Boeve, Bradley F. , Boxer, Adam L. , Rosen, Howard J. , Walsh, Christine M. , Staffaroni, Adam M. , Appleby, Brian S. , Barmada, Sami , Bozoki, Andrea C , Domoto‐Reilly, Kimiko , Galasko, Douglas , Gavrilova, Ralitza H. , Gendron, Tania F. , Geschwind, Daniel H., Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grossman, Murray, Hales, Chadwick M. , Hall, Matthew , Honig, Lawrence, Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Knopman, David, Kwan, Justin , Lavigne, Shannon B., Léger, Gabriel C. , Litvan, Irene , Mackenzie, Ian R. , Masdeu, Joseph C , McMillan, Corey T. , Mester, Carly , Molden, Joie, Pantelyat, Alexander , Pascual, Belén , Petrucelli, Leonard , Pressman, Peter , Rademakers, Rosa, Rankin, Katherine P. , Rao, Meghana , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Rojas, Julio C. , Savica, Rodolfo , Snyder, Allison , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Taylor, Jack C. , Tipton, Philip W. , Vandebergh, Marijne , Weıntraub, Sandra , Wong, Bonnie

Mayo Clinic

Neurology Open Access | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1212/wn9.0000000000000068 | PMID 41987885 Get It

Chromosome X-wide association study in multiple system atrophy identifies sex-differential risk loci
Ray, Anindita , Chia, Ruth , Rasheed, Memoona, Ece, Bayram, Jinhui, Ding, Walton, Ronald L., Diez-Fairen, Monica, Álvarez, Ignacio Morales, Fanciulli, Alessandra , Seppi, Mag Klaus, Duerr, Susanne, Leys, Fabian , Krismer, Florian , Sidoroff, Victoria , Pirker, Walter , Rascol, Olivier, Foubert-Samier, Alexandra, Meissner, Wassilios G, Tison, François , Barone, Paolo, Russillo, Maria Claudia, Marín-Lahoz, Juan, Kulisevsky, J, Torres, Soraya, Mir, Pablo, Periñán, María Teresa, Proukakis, C., Goh, Yee Yen, Parkkinen, Laura, Hu, Michele T, Saxon, Jennifer A. , Rollinson, Sara , Garland, Emily M. , Litvan, Irene, Alcalay, Roy N, Kwei, Kimberly , Lubbe, Steven, Mao, Qinwen, Flanagan, Margaret E, Castellani, Rudolph J, Ndayisaba, Alain , Calvo, Andrea, Canosa, Antonio, Bohannan, Ryan C., Norcliffe-Kaufmann, Lucy, Palma, Jose-Alberto, Dawson, Ted M, Albert, Marilyn S, Pletniková, Olga , Troncoso, Juan C, Lage, Carmen , Sánchez-Juan, Pascual, Serrano, Geidy E, Beach, Thomas G, Morris, Huw R, Clarimon, Jordi, Jaunmuktane, Zane, Révész, Tamás, Warner, Tom, Hardy, John A, Ryten, Mina, Ferrucci, Luigi, Topol, Eric, Torkamani, Ali, DeCasien, Alex R, Chiò, Adriano, Low, Philip, Wszolek, Zbigniew K, Dickson, Dennis W., Traynor, Bryan J, Gibbs, J Raphael, Dalgard, Clifton L, Ross, Owen A, Houlden, Henry, Scholz, Sonja W., Hardy, John , Dickson, Dennis W. , Ross, Owen A. , Houlden, Henry , Scholz, Sonja W. , Chia, Ruth , Proukakis, Christos , Dickson, Dennis W , Dalgard, Clifton L , Ross, Owen A , Houlden, Henry , Scholz, Sonja W , Hardy, John , Reynolds, Regina H. , Díez-Fairén, Mónica , Fanciulli, Alessandra , Stefanova, Nadia , Seppi, Klaus , Krismer, Florian, Zimprich, Alexander , Rascol, Olivier , Foubert‐Samier, Alexandra , Meissner, Wassilios G. , Tison, François , Traon, Anne Pavy‐Le , Pellecchia, Maria Teresa , Marín‐Lahoz, Juan , Kulisevsky, Jaime , Mir, Pablo , Chelban, Viorica , Wu, Lesley , Kobylecki, Christopher , Biaggioni, Italo , Litvan, Irene , Rubio, Ileana, Lubbe, Steven , Flanagan, Margaret E , Castellani, Rudolph J. , Khurana, Vikram , Mora, Gabriele , Floris, Gianluca , Moore, Anni K. , Norcliffe‐Kaufmann, Lucy , Palma, Jose-Alberto , Kaufmann, Horacio , Dawson, Ted M , Rosenthal, Liana S. , Pantelyat, Alexander , Troncoso, Juan C. , Infante, Jon , Serrano, Geidy E. , Beach, Thomas G. , Pástor, Pau , Albani, Diego , Clarimón, Jordi , Jaunmuktane, Zane , Frontzek, Karl , Warner, Thomas T. , Ferrucci, Luigi , Topol, Eric J. , Torkamani, Ali , DeCasien, Alex R. , Chiò, Adriano , Singer, Wolfgang , Cheshire, William P. , Wszołek, Zbigniew K. , Traynor, Bryan J. , Gibbs, J. Raphael

Mayo Clinic

Brain | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag062 | PMID 41684229 Get It

Abstract The human X chromosome accounts for ∼5% of the genome. Despite its size, the role of X-chromosomal variants in human diseases is not well understood, mainly due to its distinct inheritance pattern and the frequent omission of sex chromosomes from genome-wide association studies. This study used whole-genome sequencing data from 888 multiple system atrophy (MSA) cases and 7128 controls to perform an X-chromosome-wide common variant association study. Our analyses revealed two sex-differential risk loci: one located at Xq28, associated with increased risk for MSA in females [index variant: rs4898389, odds ratio (OR) = 1.69, 95% confidence interval (CI) = 1.40–2.03, P-value = 2.43 × 10⁻⁸], and another at Xp22.2 within the TBL1X gene, identified in males (index variant: rs6638956, OR = 1.48, 95%CI = 1.26–1.73, P-value = 9.92 × 10⁻⁷). In the Xq28 locus, colocalization analyses pointed to FAM3A and PLXNA3 as genes of interest. These findings emphasize the vital role of sex-differential genetic factors in the pathogenesis of MSA.